Pricing Log in Create free account
Friday 6 November 2026 Export PSNL’s income statement to Excel — free account

Personalis, Inc.

PSNL Healthcare Diagnostics & Research

Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.

Revenue
+76.6%
EPS
−33.3%
Free cash flow
−15.5%

Quarter to September 2026, against a year earlier

15.71 0.16 +1.03%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−14.6×
Dividend yield
—
F-score
4/9
Altman Z
3.35
Beneish M
−1.30
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 7.86
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 1 — — — 2 4 2 — 4 — 1
Insider Ownership 31.90%

Capital & Financial Ratios $m

Size
Market Cap 1,690.00
Revenue ttm 80.77
Net income ttm (119.33)
Free cash flow ttm (97.57)
Net debt Q (190.60)
Valuation
P/E 0.00
Forward P/E (14.60) (negative: loss-making)
Price / sales 20.71 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 7.86 (above 6: high)
Financial health
Current ratio Q 4.53 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (986.61)
Growth
Revenue growth Q +76.59% (above 0%: growing)
Operating income growth Q −52.50% (below 0%: shrinking)
EPS, this year −20.15% (below 0%: weak)
EPS, next year A +9.45%
Revenue, next year A +21.09% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +6.66%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 18.6×, against a ten-year median of 2.7×; over the ten years it ranged from −1.2× in 2022 to 22.6× in 2026.
P/S against its own 10 years 95.67%
10-year low 10-year high
P/B against its own 10 years 97.84%
10-year low 10-year high
EV/Sales against its own 10 years 94.48%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 114 185 240 191
Receivables 18 8 16 18
Inventory 10 6 6 7
Other — — — —
147 203 268 223
2023 2024 2025 Q'26
Payables 15 6 13 14
ST’ Debt — — — —
Other 8 3 2 2
47 31 40 49

Compound Annual Growth %

10y 5y 3y
Sales — (2.40%) 2.30%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 6.02% 6.19%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.25 Actual −0.30

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.28 −0.24 Beat by 0.04
Q4 FY25 −0.31 −0.26 Beat by 0.05
Q1 FY26 −0.23 −0.29 Miss by 0.06
Q2 FY26 −0.25 −0.30 Miss by 0.05

EPS $

Mar Jun Sep Dec Year
’26 (0.29) (0.30) (0.32) — —
’25 (0.18) (0.23) (0.24) (0.26) (0.91)
’24 (0.26) (0.24) (0.64) (0.23) (1.37)
’23 (0.61) (0.50) (0.60) (0.54) (2.25)
’22 (0.63) (0.60) (0.58) (0.67) (2.48)
’21 (0.29) (0.34) (0.40) (0.45) (1.49)
’20 (0.29) (0.29) (0.27) (0.34) (1.20)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 15 22 26 — —
’25 21 17 14 17 70
’24 20 23 26 17 85
’23 19 17 18 20 73
’22 15 18 15 17 65
’21 21 22 22 21 85
’20 19 19 20 20 79
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (26) (27) — —
’25 (18) (13) (22) (22) (75)
’24 (20) (11) (6) (8) (45)
’23 (16) (10) (17) (13) (56)
’22 (11) (27) (15) (17) (70)
’21 (12) (26) (18) (15) (71)
’20 (9) (15) (16) (3) (43)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (30) (27) — —
’25 (20) (13) (23) (22) (79)
’24 (21) (11) (6) (9) (47)
’23 (20) (13) (18) (17) (67)
’22 (20) (38) (36) (26) (120)
’21 (12) (30) (21) (19) (82)
’20 (9) (16) (18) (3) (46)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 9 38 65 79 85 65 73 85 70 81 +28.5% 84 110 147 +28.2%
Gross margin, % — (24.94) 31.25 33.86 25.57 37.03 20.52 24.78 31.70 22.65 16.71 +47.6 pt
EBT — (24) (20) (25) (41) (65) (113) (108) (81) (81) (119) +16.7%
EBT margin, % — (251.18) (52.63) (38.45) (52.41) (76.28) (174.14) (147.27) (96.04) (116.66) (147.70) +134.5 pt
Net income — (24) (20) (25) (41) (65) (113) (108) (81) (81) (119) +16.7%
Per share, $
Per share, $ Revenue — 3.10 12.33 3.62 2.29 1.95 1.42 1.53 1.43 0.78 0.75 (15.8%)
Earnings — (7.78) (6.49) (1.39) (1.20) (1.49) (2.48) (2.25) (1.37) (0.91) (1.17) (23.5%)
Cash flow — 0.10 1.82 (1.00) (1.24) (1.61) (1.54) (1.17) (0.76) (0.84) (0.91) n/m
Capex — (1.70) (2.56) (0.47) (0.09) (0.25) (1.09) (0.23) (0.02) (0.05) 0.00 (35.6%)
Free cash flow — (1.61) (0.74) (1.47) (1.34) (1.87) (2.63) (1.39) (0.78) (0.89) (0.91) (7.1%)
Book value — 0.00 (34.73) 5.92 5.67 7.07 4.77 2.69 3.43 2.93 1.98 n/m
Shares, m — 3 3 18 34 44 46 48 59 89 102 +52.6%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.00 0.00 3.01 16.00 7.33 1.41 1.34 4.05 10.20 20.71 4.8
P/B — 0.00 0.00 1.84 6.46 2.02 0.42 0.76 1.69 2.72 7.86 1.8
EV/Sales — 0.00 0.00 1.32 13.65 4.18 (0.89) 0.03 2.07 7.01 18.57 3.0
EV/FCF — (21.53) (21.53) (3.25) (23.38) (4.36) 0.48 (0.03) (3.77) (6.15) (14.13) (9.3)
Cash, $m
Cash, $m Operating cash flow — 0 6 (18) (43) (71) (70) (56) (45) (75) (98) n/m
Capex — (5) (8) (8) (3) (11) (50) (11) (1) (5) (9) (1.7%)
Free cash flow — (5) (2) (26) (46) (82) (120) (67) (47) (79) (98) +41.8%
Balance, $m
Balance, $m Working capital — (23) (28) 90 180 287 167 100 172 228 174 n/m
Net debt — (23) (20) (128) (203) (287) (168) (114) (185) (240) (191) +34.3%
Shareholders’ equity — — (106) 107 195 310 218 129 203 261 213 n/m
Returns, %
Returns, % ROA — (62.73) (95.45) (25.21) (20.53) (20.34) (32.88) (41.83) (32.82) (26.89) (44.66) +35.8 pt
ROIC — 0.00 0.00 0.00 0.00 (175.78) (143.04) (450.20) (237.72) (259.21) (358.37) (259.2) pt
ROE — 23.72 19.99 (16,611.92) (27.37) (25.82) (42.89) (62.31) (48.91) (35.02) (62.14) (58.7) pt
People
People Employees — — 147 182 235 326 399 225 229 260 — +8.5%
Revenue/emp, $m — 0.00 0.26 0.36 0.33 0.26 0.16 0.33 0.37 0.27 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Personalis, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ADPT Adaptive Biotechnologies Corporation $4.3B — (loss-making) — (loss-making) −10.72% (below 0%: shrinking) −66.67% (below 0%: shrinking) +201.86% (above 0%: growing) 76.24% (0.54%) Compare
CDNA CareDx, Inc. $4.0B 30.9× 36.2× +39.29% (above 0%: growing) +1,133.33% (above 0%: growing) −68.62% (below 0%: shrinking) 71.09% 5.82% Compare
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%) Compare
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92% Compare
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +76.59% (above 0%: growing) n/m −15.54% (below 0%: shrinking) 25.67% (138.76%)
OPK OPKO Health, Inc. $1.3B — (loss-making) — (loss-making) −56.87% (below 0%: shrinking) n/m −3.40% (below 0%: shrinking) 64.30% (48.02%) Compare
FRNM Freenome, Inc $1.1B — (loss-making) — — n/m +12.06% (above 0%: growing) — 0.00% Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +23.90% (above 0%: growing) n/m +56.82% (above 0%: growing) 76.75% (2.65%) Compare
Median of peers $1.9B — — +11.44% +62.50% −6.51% 70.58% (1.59%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 2 April 2026

Ownership

Directors and executive officers, together 4.20%
Merck & Co., Inc. 13.40%
Tempus AI, Inc. 12.50%
Entities affiliated with T. Rowe Price Investment Management, Inc. 10.30%
Entities affiliated with Lightspeed Venture Partners 7.80%
ARK Investment Management LLC 6.90%
Ameriprise Financial, Inc. 6.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Personalis, Inc. (PSNL) Latest News

4 Nov

Impact 3 · · Business Wire

2 Nov

Impact 3 · · MarketBeat

27 Oct

Impact 4 · · 24/7 Wall St.

26 Oct

Impact 4 · · Trefis

21 Oct

Impact 4 · · Business Wire

20 Oct

Impact 4 · · Business Wire
Impact 3 · · Simply Wall St.

21 Sep

Impact 4 · · MarketBeat

27 Aug

Impact 5 ·

26 Aug

Impact 3 · · Barchart

22 Aug

Impact 4 ·

20 Aug

Impact 3 · · Stocktwits

4 Aug

Impact 3 ·

1 Aug

Impact 4 ·

31 Jul

Impact 3 · · MarketBeat transcript

30 Jul

Impact 3 · · Barchart

22 Jul

Impact 4 · · TheStreet

21 Jul

Impact 5 · · qz.com
Impact 5 · · medicaldevice-network.com
Impact 5 ·
Impact 4 ·

20 Jul

Impact 5 ·
Impact 5 ·
Impact 5 · · MarketBeat
Impact 5 ·
Impact 5 · · Proactive Investors
Impact 5 ·
Impact 5 · · medtechdive.com
Impact 4 · · Stocktwits
Impact 4 · · Stocktwits
stockrow.com/PSNL · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com